Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 2
2010 4
2011 5
2012 5
2013 5
2014 8
2015 2
2016 1
2017 2
2018 2
2019 2
2020 4
2021 6
2022 2
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Lambertini M, et al. JAMA. 2024 Jan 2;331(1):49-59. doi: 10.1001/jama.2023.25463. JAMA. 2024. PMID: 38059899
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials.
Mastrantoni L, Garufi G, Di Monte E, Maliziola N, Pasqualoni M, Pontolillo L, Pannunzio S, Cannizzaro MC, Di Bello A, Fabi A, Palazzo A, Tortora G, Bria E, Orlandi A. Mastrantoni L, et al. Among authors: palazzo a. Ther Adv Med Oncol. 2023 May 29;15:17588359231173180. doi: 10.1177/17588359231173180. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37284523 Free PMC article.
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Garufi G, Carbognin L, Arcanà C, Parola S, Ventriglia A, Doronzo A, Garutti M, Orlandi A, Palazzo A, Fabi A, Bria E, Tortora G, Arpino G, Giuliano M, Del Mastro L, De Laurentiis M, Puglisi F. Garufi G, et al. Among authors: palazzo a. Cancer Treat Rev. 2022 Nov;110:102454. doi: 10.1016/j.ctrv.2022.102454. Epub 2022 Aug 11. Cancer Treat Rev. 2022. PMID: 35987149 Review.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Botticelli A, et al. Among authors: palazzo a. Oncologist. 2024 Apr 4;29(4):303-310. doi: 10.1093/oncolo/oyad308. Oncologist. 2024. PMID: 37995313 Free PMC article.
Abiraterone acetate in castration-resistant prostate cancer.
Iacovelli R, Palazzo A, Procopio G, Gazzaniga P, Cortesi E. Iacovelli R, et al. Among authors: palazzo a. Anticancer Drugs. 2012 Mar;23(3):247-54. doi: 10.1097/CAD.0b013e32834e696c. Anticancer Drugs. 2012. PMID: 22123334 Review.
Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials.
Duranti S, Fabi A, Filetti M, Falcone R, Lombardi P, Daniele G, Franceschini G, Carbognin L, Palazzo A, Garganese G, Paris I, Scambia G, Pietragalla A. Duranti S, et al. Among authors: palazzo a. Cancers (Basel). 2021 Oct 16;13(20):5198. doi: 10.3390/cancers13205198. Cancers (Basel). 2021. PMID: 34680350 Free PMC article. Review.
Neoadjuvant Chemotherapy in Breast Cancer: An Advanced Personalized Multidisciplinary Prehabilitation Model (APMP-M) to Optimize Outcomes.
Di Leone A, Terribile D, Magno S, Sanchez AM, Scardina L, Mason EJ, D'Archi S, Maggiore C, Rossi C, Di Micco A, Carnevale S, Paris I, Marazzi F, Masiello V, Orlandi A, Palazzo A, Fabi A, Masetti R, Franceschini G. Di Leone A, et al. Among authors: palazzo a. J Pers Med. 2021 Apr 21;11(5):324. doi: 10.3390/jpm11050324. J Pers Med. 2021. PMID: 33919061 Free PMC article. Review.
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy.
Garufi G, Carbognin L, Sperduti I, Miglietta F, Dieci MV, Mazzeo R, Orlandi A, Gerratana L, Palazzo A, Fabi A, Paris I, Franco A, Franceschini G, Fiorio E, Pilotto S, Guarneri V, Puglisi F, Conte P, Milella M, Scambia G, Tortora G, Bria E. Garufi G, et al. Among authors: palazzo a. Ther Adv Med Oncol. 2023 Mar 14;15:17588359221138657. doi: 10.1177/17588359221138657. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36936199 Free PMC article.
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L, Orlandi A, Palazzo A, Garufi G, Fabi A, Daniele G, Giannarelli D, Tortora G, Bria E. Mastrantoni L, et al. Among authors: palazzo a. EClinicalMedicine. 2023 Jan 20;56:101824. doi: 10.1016/j.eclinm.2023.101824. eCollection 2023 Feb. EClinicalMedicine. 2023. PMID: 36713467 Free PMC article.
57 results